Úspěšná léčba dasatinibem u pacientky s chronickou myeloidní leukemií po ztrátě léčebné odpovědi v terénu nově zjištěné duplicitní hematologické malignity
| Title in English | Successful treatment of dasatinib in a patient with chronic myeloid leukemia after loss of response in the field of newly discovered duplicate haematological malignancy |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.farmakoterapie.cz/c5947/uspesna-lecba-dasatinibem-u-pacientky-s-chronickou-myeloidni-leukemii-po-ztrate-lecebne-odpovedi-v-terenu-nove-zjistene-duplicitni-hematologicke-malignity |
| Keywords | chronic myeloid leukemia; dasatinib |
| Description | 919/5000 The introduction of imatinib as a prototype of tyrosine kinase inhibitors (TKI) in the therapy of patients with chronic myeloid leukemia (CML) has significantly improved the prognosis of patients, especially those diagnosed in the chronic phase (CP). Long-term follow-up of patients treated with Imatinib in the first line of the IRIS study showed that 83.3% of patients survived 10 years after initiating imatinib treatment and that CML patients were close to the overall population at this parameter. Excellent results were obtained even though almost half of the patients in the study discontinued imatinib treatment, most often due to lack of therapeutic effect or intolerance. This underscores the importance of second-line TKI treatment with second generation TKI, especially given the availability and widespread dasatinib and nilotinib, which have demonstrated long-term efficacy and good tolerability in both clinical trials and everyday clinical practice. |